. Prebiotics that enrich for anti-tumor promoting taxa in vitro. Related to Figure 1. a, Boxplot of the relative abundance of the common taxa between the ones induced by mucin (1% w/v) in mouse fecal sample culture and the ones enriched in Rnf5 -/mouse gut microbiota (culture control n = 3; culture mucin n =3 ; WT n = 30; Rnf5 -/n = 30 ). b, Boxplot of the relative abundance of the common taxa between the ones induced by inulin (1% w/v) in mouse fecal sample culture and the ones enriched in Rnf5 -/mouse gut microbiota (culture control n = 3; culture mucin n = 3; WT n = 30 ; Rnf5 -/n =30). c, Fecal samples derived from 12 healthy human subjects cultivated in the presence or absence of 1% prebiotic (control n=6; mucin n=12; inulin n=12). 16S rDNA sequences corresponding to Bifidobacterium, Bacteroides and Akkermansia muciniphila. Data are one experiment (a, b) representative of two independent experiments (c). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey's correction. ndLN n = 8). b, Serum chemokines in WT mice with or without mucin treatment at 10 days after tumor inoculation (n = 10). Data are representative of two independent experiments. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann-Whitney U test. a, Quantification of NRAS Q61K tumor-infiltrating IFN-γ-producing CD4 + and CD8 + T cells from C57BL/6 mice treated with MEKi + mucin or inulin (n=8). b, Boxplot of the relative abundance of the taxa enriched in inulin treated-mice gut microbiota that are negatively correlated with tumor size (n = 10). The fecal samples were taken at different time points (before inulin treatment, before tumor injection, before MEKi treatment and before tumor collection). c, Boxplot of the relative abundance of the taxa enriched in gut microbiota of mucin treated-mice, which are negatively correlated with tumor size (n = 10). The fecal samples were taken at different time points (before mucin treatment, before tumor injection, before MEKi treatment and before tumor collection) following the innoculation of YUMM1.5 tumor cells. Data are representative of two independent experiments. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey's correction. Figure 6. a, Growth of Yumm1.5 tumors in C57BL/6 mice provided with butyrate, propionate and acetate (150 mM) and the combination of all three (50 mM each) in drinking water 14 days prior to and during tumor inoculation (n =12). b, SW1 tumor growth in ASF-bearing C3H/HeN mice undergoing oral gavage with or without mucin prior to tumor inoculation (n = 15). c, MHC I, MHC II, CD40 and CD86 expression (MFI) on BMDCs left untreated (control) or stimulated with 0.05 mg/ml and 0.5 mg/ml mucin and inulin in vitro (n = 6). d, qRT-PCR analysis of the indicated cytokine and chemokine mRNAs in CD8 + T cells left untreated (control) or stimulated with 0.05 mg/ml and 0.5 mg/ml mucin and inulin in vitro (n = 4). e, qRT-PCR analysis of proinflammatory gene mRNA levels in IECs in mucin or inulin-treated mice (n = 6). Data are representative of two independent experiments. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-way ANOVA with Tukey's correction(a and b) or oneway ANOVA with Tukey's correction (c, d and e). Growth of Yumm1.5 mouse melanoma cells in C57BL/6 mice that were fed with 0 or 3% mucin in drinking water and (or) a diet enriched 15% inulin, starting 14 days prior to and during tumor inoculation (control n = 7; mucin n=5; inulin n=7; mucin+inulin n=8). Data are representative of two independent experiments.Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-way ANOVA with Tukey's correction.
Figure S5. Effect of mucin and inulin on the activation of DCs, T cells and IECs. Related to

